Teladoc (TDOC) ended the recent trading session at $9.39, demonstrating a +0.21% swing from the preceding day's closing price. This change lagged the S&P 500's 0.55% gain on the day. Meanwhile, the Dow gained 0.62%, and the Nasdaq, a tech-heavy index, added 0.63%. Heading into today, shares of the telehealth services provider had lost 5.83% over the past month, lagging the Medical sector's gain of 0.19% and the S&P 500's gain of 4.28% in that time. Analysts and investors alike will be keeping a close eye on the performance of Teladoc in its upcoming earnings disclosure. On that day, Teladoc is projected to report earnings of -$0.35 per share, which would represent year-over-year growth of 12.5%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $649.56 million, down 0.44% from the year-ago period. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.05 per share and revenue of $2.65 billion, indicating changes of +21.64% and +1.8%, respectively, compared to the previous year. It's also important for investors to be aware of any recent modifications to analyst estimates for Teladoc. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.17% lower. At present, Teladoc boasts a Zacks Rank of #3 (Hold). The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 102, placing it within the top 41% of over 250 industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow TDOC in the coming trading sessions, be sure to utilize Zacks.com. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teladoc Health, Inc. (TDOC):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Teladoc (TDOC) Ascends But Remains Behind Market: Some Facts to Note
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...